FDA grants enzalutamide Priority Review for prostate cancer

FDA accepted and granted Priority Review to an NDA from Medivation Inc. (NASDAQ:MDVN) for enzalutamide (formerly MDV3100) to treat castration-resistant prostate cancer (CRPC) in patients previously tr...